Compare · ICU vs WST
ICU vs WST
Side-by-side comparison of SeaStar Medical Holding Corporation (ICU) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICU and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.61B, about 1518.1x ICU ($16.9M).
- Over the past year, ICU is down 37.1% and WST is up 63.1% - WST leads by 100.3 points.
- ICU has been more active in the news (11 items in the past 4 weeks vs 5 for WST).
- WST has more recent analyst coverage (18 ratings vs 0 for ICU).
- Company
- SeaStar Medical Holding Corporation
- West Pharmaceutical Services Inc.
- Price
- $4.15-2.81%
- $361.88-0.09%
- Market cap
- $16.9M
- $25.61B
- 1M return
- +36.96%
- +9.84%
- 1Y return
- -37.14%
- +63.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 5
- Recent ratings
- 0
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest ICU
- SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
- Chief Executive Officer Schlorff Eric was granted 10,288 shares, increasing direct ownership by 26% to 50,140 units (SEC Form 4)
- Chief Medical Officer Chung Kevin was granted 7,202 shares, increasing direct ownership by 35% to 28,021 units (SEC Form 4)
- Director Vincent Bernadette N was granted 4,000 shares, increasing direct ownership by 95% to 8,200 units (SEC Form 4)
- Director Neuman John was granted 4,000 shares, increasing direct ownership by 33% to 16,200 units (SEC Form 4)
- Director Van Heel Kenneth was granted 4,000 shares, increasing direct ownership by 50% to 11,940 units (SEC Form 4)
- Director Baird Jennifer A was granted 4,000 shares, increasing direct ownership by 60% to 10,620 units (SEC Form 4)
- SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Leadership Update
- SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits